Vivasor, Inc.

Sorrento Therapeutics, Inc.

Henry Hongjun Ji

Gunnar F Kaufmann

Alexis Nahama

Tong Zhu

Yanwen Fu

Yanliang Zhang

Heehyoung Lee

Bei Bei Ding

Wenzhong Guo

There is disclosed a method for treating Parkinson's Disease (PD) comprising administering an effective amount of Resiniferatoxin (RTX) by an intrathecal or intracisternal administration. In some embodiments, the dose of RTX for an adult human is from about 0.1 μg to about 100 μg.

Methods for treating Parkinson's disease by administering resiniferatoxin

The present disclosure provides dimeric antigen receptors (DAR) constructs comprising a heavy chain binding region on one polypeptide chain and a light chain binding region on a separate polypeptide chain. The two polypeptide chains that make up the dimeric antigen receptors can dimerize to form an antigen binding domain. The dimeric antigen receptors have antibody-like properties as they bind specifically to a target antigen. The dimeric antigen receptors can be used for directed cell therapy.

Dimeric antigen receptors

Disclosed herein are methods of administering resiniferatoxin (RTX) for treatment of osteoarthritis (OA) pain, and compositions for use in such methods.

Method for treating osteoarthritis pain by administering resiniferatoxin

Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Henry Hongjun Ji